Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predictive Value of Cytocapacity Test with Lenograstim in Lymphoproliferative Diseases
NCT01085058Phase 3Completed
- Sponsor
- Wisp
- Start
- May 2003
- Primary completion
- Dec 2004
- Modality
- Cytokines & Interferons
01
Overview
A Phase 3 trial of lenograstim in Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), multiple myeloma (MM), sponsored by Wisp. Started May 2003; status: completed.
02
Drugs
lenograstim
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01085058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01085058.